Caption Management’s Altimmune ALT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-21,200
Closed -$76.5K 1512
2025
Q4
$76.5K Buy
+21,200
New +$92.4K ﹤0.01% 1453
2025
Q3
Sell
-322,800
Closed -$1.25M 1634
2025
Q2
$1.25M Sell
322,800
-187,000
-37% -$1.01M 0.01% 874
2025
Q1
$2.55M Buy
+509,800
New +$3.23M 0.02% 608
2024
Q3
Sell
-25,000
Closed -$166K 1243
2024
Q2
$166K Buy
+25,000
New +$184K ﹤0.01% 977
2023
Q2
Sell
-1,490,200
Closed -$6.29M 1077
2023
Q1
$6.29M Buy
1,490,200
+942,900
+172% +$11.2M 0.12% 194
2022
Q4
$9M Sell
547,300
-75,900
-12% -$853K 0.14% 178
2022
Q3
$7.96M Buy
+623,200
New +$9.2M 0.11% 220
2022
Q2
Sell
-381,300
Closed -$2.32M 1412
2022
Q1
$2.32M Hold
381,300
0.03% 704
2021
Q4
$3.49M Hold
381,300
0.04% 586
2021
Q3
$4.31M Buy
+381,300
New +$4.64M 0.05% 512

Other funds holding ALT

Caption Management's ALT Position: Q1 2026 in Review

Caption Management held its Altimmune (ALT) position steady in Q1 2026 at 74,438 shares worth $229K. The position accounts for ﹤0.01% of the portfolio, ranked #1328.

Caption Management first reported a position in ALT in Q3 2021 and has held it in 11 quarters since. The position peaked at $3.8M in Q2 2025. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

  • Caption Management held 74,438 shares of Altimmune worth $229K as of Q1 2026.
  • Caption Management left its Altimmune share count unchanged in Q1 2026.
  • Altimmune made up ﹤0.01% of Caption Management's portfolio in Q1 2026, its #1328 holding.
  • Caption Management first reported a position in Altimmune in Q3 2021 and has held it in 11 quarters since.
  • Caption Management's Altimmune position peaked at $3.8M in Q2 2025.
  • 173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.